Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free AXSM Stock Alerts $70.25 -2.83 (-3.87%) (As of 03:35 PM ET) Add Compare Share Share Today's Range$69.92▼$73.1450-Day Range$65.72▼$93.4652-Week Range$55.02▼$98.40Volume362,792 shsAverage Volume724,250 shsMarket Capitalization$3.33 billionP/E RatioN/ADividend YieldN/APrice Target$119.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside69.5% Upside$119.67 Price TargetShort InterestBearish16.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.76Based on 6 Articles This WeekInsider TradingSelling Shares$3.99 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.81) to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.46 out of 5 starsMedical Sector97th out of 909 stocksPharmaceutical Preparations Industry31st out of 423 stocks 4.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.15% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 4.79%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.1 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 17 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 17 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,994,220.00 in company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.81) to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -13.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -13.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 17.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesApril 2, 2024 | insidertrades.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 24,662 Shares of StockApril 20, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Expected to Post Q1 2024 Earnings of ($1.26) Per ShareApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 18, 2024 | markets.businessinsider.comStrong Buy on Axsome’s Auvelity Amidst Competitive MDD MarketApril 16, 2024 | markets.businessinsider.comAuvelity’s Strong Performance Sustains Buy Rating for Axsome TherapeuticsApril 15, 2024 | globenewswire.comAxsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingApril 15, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by AnalystsApril 10, 2024 | fool.com2 Under-the-Radar Growth Stocks to ConsiderApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 10, 2024 | globenewswire.comAxsome Therapeutics to Report First Quarter 2024 Financial Results on May 6April 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics Amid Strong Clinical Pipeline and Market Expansion PotentialApril 2, 2024 | finance.yahoo.comInsider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)April 1, 2024 | globenewswire.comAxsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderMarch 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Axsome Therapeutics: Diverse Portfolio and Market Potential Despite ChallengesMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 26, 2024 | markets.businessinsider.comMaintaining Hold on Axsome Therapeutics: Weighing AXS-12’s Modest Efficacy Against Competitive and Market RisksMarch 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)March 25, 2024 | msn.comWhat's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?March 25, 2024 | globenewswire.comAxsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsMarch 25, 2024 | reuters.comAxsome Therapeutics sleep disorder therapy succeeds in late-stage trialMarch 25, 2024 | globenewswire.comAxsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyMarch 23, 2024 | finance.yahoo.comBuying These Dirt-Cheap Stocks Could Be a Brilliant MoveMarch 23, 2024 | fool.comBuying These Dirt-Cheap Stocks Could Be a Brilliant MoveMarch 22, 2024 | finance.yahoo.comAxsome Triumphs Over Major Depressive Disorder With AuvelityMarch 19, 2024 | msn.comBaird starts Axsome at outperform, cites upcoming dataMarch 19, 2024 | finanznachrichten.deAxsome Therapeutics, Inc.: Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderMarch 19, 2024 | investing.comBaird starts Axsome Therapeutics stock at Outperform on promising trial outlookSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/24/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$119.67 High Stock Price Target$190.00 Low Stock Price Target$81.00 Potential Upside/Downside+63.7%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-88.41% Pretax Margin-88.06% Return on Equity-70.67% Return on Assets-27.47% Debt Debt-to-Equity Ratio0.93 Current Ratio3.63 Quick Ratio3.52 Sales & Book Value Annual Sales$270.60 million Price / Sales12.79 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book18.09Miscellaneous Outstanding Shares47,370,000Free Float35,767,000Market Cap$3.46 billion OptionableOptionable Beta1.13 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Nick Pizzie CPA (Age 49)M.B.A., Chief Financial Officer Comp: $732.94kMr. Mark L. Jacobson (Age 41)COO & Secretary Comp: $784.66kMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kDr. Amanda Jones Pharm.D. (Age 41)Senior Vice President of Clinical Development Ms. Lori Englebert M.B.A. (Age 46)Executive Vice President of Commercial & Business Development Joseph Debrah-Afful CPAM.B.A., Director of FinanceMore ExecutivesKey CompetitorsPrestige Consumer HealthcareNYSE:PBHInsmedNASDAQ:INSMBiohavenNYSE:BHVNUltragenyx PharmaceuticalNASDAQ:RARECymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsRaymond James Financial Services Advisors Inc.Sold 815 shares on 4/23/2024Ownership: 0.037%Wesbanco Bank Inc.Bought 8,300 shares on 4/23/2024Ownership: 0.018%Hennion & Walsh Asset Management Inc.Bought 8,867 shares on 4/17/2024Ownership: 0.147%Janiczek Wealth Management LLCBought 1,213 shares on 4/15/2024Ownership: 0.003%Yarbrough Capital LLCBought 5,054 shares on 4/10/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price target for 2024? 12 analysts have issued 12-month price targets for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $190.00. On average, they expect the company's stock price to reach $119.67 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2024? Axsome Therapeutics' stock was trading at $79.59 at the beginning of the year. Since then, AXSM shares have decreased by 11.3% and is now trading at $70.59. View the best growth stocks for 2024 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AXSM earnings forecast. How can I listen to Axsome Therapeutics' earnings call? Axsome Therapeutics will be holding an earnings conference call on Monday, May 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its earnings results on Tuesday, February, 20th. The company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($1.21) by $0.48. The business earned $71.53 million during the quarter, compared to analyst estimates of $70.38 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 70.67% and a negative net margin of 88.41%. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.15%), Raymond James Financial Services Advisors Inc. (0.04%), Wesbanco Bank Inc. (0.02%), Yarbrough Capital LLC (0.01%) and Janiczek Wealth Management LLC (0.00%). Insiders that own company stock include Mark Coleman, Mark E Saad, Mark L Jacobson, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXSM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
